Market Research Logo

Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2018

Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, “Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2018 provides an overview of Lung Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Lung Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Lung Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Lung Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Lung Cancer Diagnostic Tests Overview
3 Products under Development
3.1 Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development
3.2 Lung Cancer Diagnostic Tests - Pipeline Products by Territory
3.3 Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
3.4 Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
3.5 Lung Cancer Diagnostic Tests - Ongoing Clinical Trials
4 Lung Cancer Diagnostic Tests - Pipeline Products under Development by Companies
4.1 Lung Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development
4.2 Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development
5 Lung Cancer Diagnostic Tests Companies and Product Overview
5.1 A&G Pharmaceutical Inc Company Overview
5.2 Abbott Diagnostics Company Overview
5.3 Abcodia Ltd Company Overview
5.4 Aberystwyth University Company Overview
5.5 Abnova Corp Company Overview
5.6 Acobiom Company Overview
5.7 Advanced Marker Discovery SL Company Overview
5.8 AIT Austrian Institute of Technology GmbH Company Overview
5.9 Almac Diagnostics Ltd Company Overview
5.10 ANGLE plc Company Overview
5.11 Armune BioScience Inc Company Overview
5.12 Aurelium BioPharma Inc. Company Overview
5.13 Avant Diagnostics, Inc. Company Overview
5.14 BARD1 Life Sciences Ltd Company Overview
5.15 BioAffinity Technologies, Inc. Company Overview
5.16 Biocept Inc Company Overview
5.17 BioChain Institute Inc Company Overview
5.18 Biodesix Inc Company Overview
5.19 Biological Dynamics, Inc. Company Overview
5.20 BioMark Diagnostics Inc. Company Overview
5.21 BioMarker Strategies LLC Company Overview
5.22 BioNTech AG Company Overview
5.23 BioSystems International Company Overview
5.24 Cancer Genetics Inc Company Overview
5.25 Cancer Research Technology Ltd Company Overview
5.26 Cangen Biotechnologies Inc (Inactive) Company Overview
5.27 CDI Laboratories Inc Company Overview
5.28 Celcuity LLC Company Overview
5.29 Cellanyx Diagnostics, Inc. Company Overview
5.30 CeMines, Inc. (Inactive) Company Overview
5.31 Cepheid Company Overview
5.32 Ceres Nanosciences Inc Company Overview
5.33 Cernostics Inc Company Overview
5.34 ChemImage Corp Company Overview
5.35 Children's Hospital Boston Company Overview
5.36 Clarient Inc Company Overview
5.37 Courtagen Life Sciences Inc Company Overview
5.38 Creatv MicroTech, Inc Company Overview
5.39 DiagnoCure Inc. (Inactive) Company Overview
5.40 EDP Biotech Corporation Company Overview
5.41 Emory University Company Overview
5.42 Enterome Bioscience SA Company Overview
5.43 Epic Sciences Inc Company Overview
5.44 Epigenomics AG Company Overview
5.45 Eventus Diagnostics Inc (Inactive) Company Overview
5.46 Exact Sciences Corp Company Overview
5.47 Exiqon A/S Company Overview
5.48 Exosomics Siena SpA Company Overview
5.49 Fahy Gurteen UK Ltd Company Overview
5.50 Fina Biotech SL Company Overview
5.51 Foundation Medicine Inc Company Overview
5.52 French National Institute of Health and Medical Research Company Overview
5.53 Fujirebio Diagnostics Inc Company Overview
5.54 Gene Express, Inc. (Inactive) Company Overview
5.55 GeneCentric Diagnostics, Inc. Company Overview
5.56 Global Discovery Biosciences Corporation Company Overview
5.57 GlycoZym Company Overview
5.58 Guardant Health Inc Company Overview
5.59 ImmunoCellular Therapeutics Ltd Company Overview
5.60 Insight Genetics Inc Company Overview
5.61 InterGenetics Inc Company Overview
5.62 IV Diagnostics Inc Company Overview
5.63 Janssen Biotech Inc Company Overview
5.64 Louisville Bioscience, Inc. Company Overview
5.65 MDNA Life Sciences Inc Company Overview
5.66 MDxHealth SA Company Overview
5.67 MEDITE Cancer Diagnostics Inc Company Overview
5.68 Memory Dx LLC Company Overview
5.69 Merrimack Pharmaceuticals Inc Company Overview
5.70 Metabolon Inc Company Overview
5.71 Metanomics Health GmbH Company Overview
5.72 MetaStat Inc Company Overview
5.73 Milagen Inc Company Overview
5.74 Nanocytomics LLC Company Overview
5.75 NEOMICS Co Ltd Company Overview
5.76 NovaGray Company Overview
5.77 Novel Bio-spectrum Technologies Inc (Inactive) Company Overview
5.78 Oncimmune (USA) LLC Company Overview
5.79 OncoCyte Corp Company Overview
5.80 Oncolome Diagnostics Inc (Inactive) Company Overview
5.81 Onconome, Inc. (Inactive) Company Overview
5.82 OncoStem Diagnostics Pvt. Ltd Company Overview
5.83 On-Q-ity, Inc. (Inactive) Company Overview
5.84 OPKO Health Inc Company Overview
5.85 Orion Genomics LLC Company Overview
5.86 OTraces Inc. Company Overview
5.87 PeriRx Inc Company Overview
5.88 PleX Diagnostics Inc (Inactive) Company Overview
5.89 Precision Biologics Inc Company Overview
5.90 PreMD Inc (Inactive) Company Overview
5.91 Proplex Technologies LLC Company Overview
5.92 Proteome Sciences Plc Company Overview
5.93 Proteomika Company Overview
5.94 Quest Diagnostics Inc Company Overview
5.95 Research Center Borstel Company Overview
5.96 Roche Diagnostics International Ltd Company Overview
5.97 Rosetta Genomics Ltd Company Overview
5.98 Roswell Park Cancer Institute Company Overview
5.99 Savicell Diagnostic Ltd. Company Overview
5.100 Sengenics International Pte Ltd Company Overview
5.101 Sienna Cancer Diagnostics Ltd Company Overview
5.102 Simon Fraser University Company Overview
5.103 Sividon Diagnostics GmbH Company Overview
5.104 SomaLogic Inc Company Overview
5.105 Southern Illinois University Carbondale Company Overview
5.106 Syndax Pharmaceuticals Inc Company Overview
5.107 Sysmex Corp Company Overview
5.108 The Prince Charles Hospital Company Overview
5.109 Thermo Fisher Scientific Inc Company Overview
5.110 Transgene SA Company Overview
5.111 Treos Bio Inc Company Overview
5.112 Universal Diagnostics SL Company Overview
5.113 University of California San Francisco Company Overview
5.114 University of Chicago Company Overview
5.115 University of Colorado Company Overview
5.116 University of Maryland Company Overview
5.117 University of Queensland Company Overview
5.118 University of South Florida Company Overview
5.119 University of Strathclyde Company Overview
5.120 US Biomarkers Inc Company Overview
5.121 Vanderbilt University Company Overview
5.122 Ventana Medical Systems Inc Company Overview
5.123 Viomics Inc. Company Overview
5.124 VisionGate Inc Company Overview
5.125 Vitatex Inc. Company Overview
5.126 VolitionRX Ltd Company Overview
5.127 Weizmann Institute of Science Company Overview
5.128 XEPTAGEN SpA Company Overview
5.129 Zetiq Technologies Ltd Company Overview
5.130 ZORA Biosciences Oy Company Overview
6 Lung Cancer Diagnostic Tests - Recent Developments
6.1 Jul 02, 2018: Novartis plans to spin-off eye care unit into standalone entity
6.2 Jul 02, 2018: Mayo researchers find off/on switch for DNA repair protein
6.3 Jul 02, 2018: Veracyte Chairman and CEO to Speak at MedCity CONVERGE
6.4 Jun 14, 2018: VisionGate Announces Board Change
6.5 Jun 13, 2018: Rohan Hastie Named as Metabolon CEO Following the Retirement of Its Co-Founder, John Ryals
6.6 Jun 12, 2018: GSK announces changes to Vaccines and Global Manufacturing & Supply leadership
6.7 Jun 12, 2018: OGT expands custom NGS cancer panel content
6.8 Jun 12, 2018: Change at the top of the Segment Advanced Therapies at Siemens Healthineers
6.9 Jun 11, 2018: Enzo Biochem Announces Third Quarter Fiscal 2018 Financial Results
6.10 Jun 08, 2018: Cancer Research UK Appoints Tony Hickson As New chief business officer
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development
Table 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory
Table 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
Table 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
Table 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials
Table 6: Lung Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development
Table 7: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development
Table 8: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Onco 88 - Lung Cancer - Product Status
Table 10: Onco 88 - Lung Cancer - Product Description
Table 11: OncoStain 88 - Lung Cancer - Product Status
Table 12: OncoStain 88 - Lung Cancer - Product Description
Table 13: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
Table 14: ARCHITECT c4000 System - NSE Assay - Product Status
Table 15: ARCHITECT c4000 System - NSE Assay - Product Description
Table 16: ARCHITECT c8000 System - NSE Assay - Product Status
Table 17: ARCHITECT c8000 System - NSE Assay - Product Description
Table 18: ARCHITECT ci4100 Integrated System - NSE Assay - Product Status
Table 19: ARCHITECT ci4100 Integrated System - NSE Assay - Product Description
Table 20: ARCHITECT ci8200 Integrated System - NSE Assay - Product Status
Table 21: ARCHITECT ci8200 Integrated System - NSE Assay - Product Description
Table 22: ARCHITECT i1000SR System - NSE Assay - Product Status
Table 23: ARCHITECT i1000SR System - NSE Assay - Product Description
Table 24: ARCHITECT i2000SR Integrated System - Neuron-Specific Enolase Assay - Product Status
Table 25: ARCHITECT i2000SR Integrated System - Neuron-Specific Enolase Assay - Product Description
Table 26: PRAME Antigen Lung Cancer Assay - Product Status
Table 27: PRAME Antigen Lung Cancer Assay - Product Description
Table 28: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Diagnostic Assay - Lung Cancer - Product Status
Table 30: Diagnostic Assay - Lung Cancer - Product Description
Table 31: MCM Test - Lung Cancer - Product Status
Table 32: MCM Test - Lung Cancer - Product Description
Table 33: Aberystwyth University Pipeline Products & Ongoing Clinical Trials Overview
Table 34: Diagnostic Biomarker Test - Lung Cancer - Product Status
Table 35: Diagnostic Biomarker Test - Lung Cancer - Product Description
Table 36: Abnova Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 37: Diagnostic Test - ACTN4 - Product Status
Table 38: Diagnostic Test - ACTN4 - Product Description
Table 39: Acobiom Pipeline Products & Ongoing Clinical Trials Overview
Table 40: Companion Diagnostic Test - Lung Cancer - Product Status
Table 41: Companion Diagnostic Test - Lung Cancer - Product Description
Table 42: Diagnostic/Prognostic Assay - Lung Cancer - Product Status
Table 43: Diagnostic/Prognostic Assay - Lung Cancer - Product Description
Table 44: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview
Table 45: Predictive Diagnostic Test - Lung Cancer - Product Status
Table 46: Predictive Diagnostic Test - Lung Cancer - Product Description
Table 47: Prognostic Test - Lung Cancer - Product Status
Table 48: Prognostic Test - Lung Cancer - Product Description
Table 49: AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 50: Biomarker Assay - Lung Cancer - Product Status
Table 51: Biomarker Assay - Lung Cancer - Product Description
Table 52: Almac Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 53: Prognostic Test - Early Stage Lung Cancer - Product Status
Table 54: Prognostic Test - Early Stage Lung Cancer - Product Description
Table 55: Prognostic Test - NSCLC - Product Status
Table 56: Prognostic Test - NSCLC - Product Description
Table 57: ANGLE plc Pipeline Products & Ongoing Clinical Trials Overview
Table 58: Parsortix-Based Test - Lung Cancer - Product Status
Table 59: Parsortix-Based Test - Lung Cancer - Product Description
Table 60: Armune BioScience Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 61: Diagnostic Test - Lung Cancer - Product Status
Table 62: Diagnostic Test - Lung Cancer - Product Description
Table 63: Aurelium BioPharma Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 64: Lung Cancer Screening Test - Product Status
Table 65: Lung Cancer Screening Test - Product Description
Table 66: Avant Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 67: TheraLink Assay - Non-Small Cell Lung Cancer - Product Status
Table 68: TheraLink Assay - Non-Small Cell Lung Cancer - Product Description
Table 69: BARD1 Life Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 70: BARD1 Lung Cancer Test - Product Status
Table 71: BARD1 Lung Cancer Test - Product Description
Table 72: BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 73: CyPath Lung - Product Status
Table 74: CyPath Lung - Product Description
Table 75: Biocept Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 76: Companion Diagnostic Target Selector Test - SCLC - Product Status
Table 77: Companion Diagnostic Target Selector Test - SCLC - Product Description
Table 78: MicroRNA Test - Lung Cancer - Product Status
Table 79: MicroRNA Test - Lung Cancer - Product Description
Table 80: BioChain Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 81: Blood - Based Lung Cancer Test - Product Status
Table 82: Blood - Based Lung Cancer Test - Product Description
Table 83: BioChain Institute Inc - Ongoing Clinical Trials Overview
Table 84: Blood - Based Lung Cancer Test - Biochain Clinical Trial on Novel, Blood-based Lung Cancer Test
Table 85: Biodesix Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 86: PD-L1 Blood Based Diagnostic Test - Product Status
Table 87: PD-L1 Blood Based Diagnostic Test - Product Description
Table 88: TAm-Seq NGS Lung Cancer Test - Product Status
Table 89: TAm-Seq NGS Lung Cancer Test - Product Description
Table 90: VeriStrat - NSCLC - Product Status
Table 91: VeriStrat - NSCLC - Product Description
Table 92: Biodesix Inc - Ongoing Clinical Trials Overview
Table 93: VeriStrat - NSCLC - An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects with Non-small Cell Lung Cancer
Table 94: PD-L1 Blood Based Diagnostic Test - Concordance of Immunohistochemistry and a New Blood-based Expression Assay for the Detection of PD-L1 in Patients Diagnosed with Non-small Cell Lung Cancer
Table 95: Biological Dynamics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 96: OncoState Lung Assay - Product Status
Table 97: OncoState Lung Assay - Product Description
Table 98: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 99: Metabolomics-based Diagnostic Assay - Lung Cancer - Product Status
Table 100: Metabolomics-based Diagnostic Assay - Lung Cancer - Product Description
Table 101: BioMark Diagnostics Inc. - Ongoing Clinical Trials Overview
Table 102: Metabolomics-based Diagnostic Assay - Lung Cancer - Clinical Trial with Patented Non-invasive, Urine-based Assay to Measure Response to Treatment for Lung Cancer
Table 103: BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 104: Ex Vivo Biomarker Test - Lung Cancer - Product Status
Table 105: Ex Vivo Biomarker Test - Lung Cancer - Product Description
Table 106: PathMAP NSCLC - Product Status
Table 107: PathMAP NSCLC - Product Description
1.2 List of Figures
Figure 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development
Figure 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory
Figure 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
Figure 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
Figure 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report